Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

British Journal of Haematology

Volumn 162, Issue 4, 2013, Pages 483-488

  Chen, Christine I ^a   Masih Khan, Esther ^a   Jiang, Haiyan ^a   Rabea, Ahmed ^a   Cserti Gazdewich, Christine ^b   Jimenez Zepeda, Victor H ^a   Chu, Chia Min ^a   Kukreti, Vishal ^a   Trudel, Suzanne ^a   Tiedemann, Rodger ^a   Tsang, Richard ^a   Reece, Donna E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Central nervous system; Immunomodulatory drugs; Intrathecal chemotherapy; Leptomeningeal; Multiple myeloma

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; METHOTREXATE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM MYELOMA; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CRANIOSPINAL IRRADIATION; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; LEPTOMENINX; LONG TERM SURVIVAL; MALE; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKULL IRRADIATION; SYSTEMIC THERAPY;

CENTRAL NERVOUS SYSTEM; IMMUNOMODULATORY DRUGS; INTRATHECAL CHEMOTHERAPY; LEPTOMENINGEAL; MULTIPLE MYELOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CENTRAL NERVOUS SYSTEM; CISPLATIN; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SPINAL; KAPLAN-MEIER ESTIMATE; MALE; MENINGES; MIDDLE AGED; MULTIPLE MYELOMA; ORBIT; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SPINE; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84880698403     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12414     Document Type: Article

References (17)

1. Adams, J., Palombella, V.J., Sasville, E.A., Johson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615-2622.
2. Avet-Loiseau, H., Leleu, X., Roussel, M., Moreau, P., Guerin-Charbonnel, C., Caillot, D., Marit, G., Benboubker, L., Voillat, L., Mathiot, C., Kolb, B., Macro, M., Campion, L., Wetterwald, M., Stoppa, A., Hulin, C., Facon, T., Attal, M., Minvielle, S. & Harousseau, J. (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). Journal of Clinical Oncology, 28, 4630-4634.
3. Bender, R. (2011) Adjusting for multiple testing - when and how? Journal of Clinical Epidemiology, 54, 343-349.
4. Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. & Bennett, M.K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383-6391.
5. Durie, B., Harousseau, J., Miguel, J., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Atttal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
6. Fassas, A.B., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E., Sethi, R., Desikan, R., Siegel, D., Badros, A., Toor, A., Zangari, M., Morris, C., Angtuaco, E., Mathew, S., Wilson, C., Hough, A., Harik, S., Barlogie, B. & Tricot, G. (2002) Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. British Journal of Haematology, 117, 103-108.
7. Gangatharan, S.A., Carney, D.A., Prince, H.M., Wolf, M.M., Januszewicz, E.H., Ritchie, D.S. & Harrison, S.J. (2011) Emergence of central nervous system myeloma in the era of novel agents. Hematological oncology, 30, 170-174.
8. Gerrie, A., Trieu, Y., Cheng, I., Mikhael, J., Panzarella, T., Stewart, A. & Chen, C. (2011) D(T) Pace as salvage therapy for aggressive or refractory multiple myeloma (MM). Haematologica, 96, S109.
9. Gozzetti, A., Cerase, A., Lotti, F., Rossi, D., Palumbo, A., Petrucci, M., Patriarca, F., Nozzoli, C., Cavo, M., Offidani, M., Floridia, M., Berretta, S., Vallone, R., Musto, P. & Lauria, F. (2012) Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer, 118, 1574-1584.
10. Hattori, Y., Yabe, M., Okamoto, S., Morita, K., Tanigawara, Y. & Ikeda, Y. (2006) Thalidomide for the treatment of leptomeningeal multiple myeloma. European Journal of Haematology, 76, 358-359.
11. Kumar, S., Rajkumar, S., Dispenzieri, A., Lacy, M., Hayman, S., Buadi, F., Zeldenrust, S., Dingli, D., Russell, S., Lust, J., Greipp, P., Kyle, R. & Gertz, M. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
12. Muscal, J., Sun, Y., Nuchtern, J., Dauser, R., McGuffey, L., Gibson, B. & Berg, S. (2012) Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemotherapy and Pharmacology, 69, 943-947.
13. Musto, P., Rossini, F., Gay, F., Pitini, V., Guglielmelli, T., D'Arena, G., Ferrara, F., Filardi, N., Guariglia, R. & Palumbo, A. (2007) Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer, 109, 2285-2290.
14. Neben, K., Lokhorst, H., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I., Weisel, K., Pfreundschuh, M., Scheid, C., Duhrsen, U., OLindemann, W., Schmidt-Wolf, I., Peter, N., Teschendorf, C., Martin, H., Haenel, M., Derigs, H., Raab, M., Ho, A., van de Velde, H., Hose, D., Sonneveld, P. & Goldschmidt, H. (2012) Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood, 119, 940-948.
15. Nieuwenhuizen, L. & Biesma, D.H. (2008) Central nervous system myelomatosis: review of the literature. European Journal of Haematology, 80, 1-9.
16. Petersen, S.L., Wagner, A. & Gimsing, P. (1999) Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. American Journal of Hematology, 62, 228-233.
17. Williamson, M.J., Blank, J.L., Bruzzese, F.J., Cao, Y., Daniels, J.S., Dick, L.R., Labutti, J., Mazzola, A.M., Patil, A.D., Reimer, C.L., Solomon, M.S., Stirling, M., Tian, Y., Tsu, C.A., Weatherhead, G.S., Zhang, J.X. & Rolfe, M. (2006) Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Molecular Cancer Therapeutics, 5, 3052-3061.